-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。POOLは、2026年第1四半期の調整後EPSが1.43ドルとなり、前年同期比8.4%増で、市場予想の1.37ドルを上回りました。売上高は11億3,800万ドルで、前年同期比6.2%増となり、保守関連製品の好調と裁量支出の緩やかな改善により、市場予想の10億9,800万ドルを上回りました。前年同期比の比較が容易になり、裁量支出の安定化の兆しが見られることから、ガイダンスは達成可能と見ています。 POOLは通期EPSガイダンスを10.87ドル~11.17ドルに据え置き、中間値は市場コンセンサスと一致し、2022年以来初めてとなる3%のEPS成長を示唆している。季節的な構成の逆風により、粗利益率は20bps低下して29.0%となったが、SG&Aの伸びが鈍化したことで営業レバレッジが効き、営業利益率は7.3%で安定している。在庫水準は14%増加して17億ドルとなり、購入水準の上昇を反映している。在庫水準の上昇は、予想される需要の改善または潜在的な利益率への圧力のいずれかを示す可能性があるため、監視すべき重要な指標である。当社は、マクロ経済の継続的な変動と住宅市場の低迷を、裁量的支出に圧力をかける可能性のある主要なリスクと見なしている。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.